Date: March 1-4, 2020 Location: Moscone South Convention Center, San Francisco, CA Attend our presentation or schedule a meeting with us here. Presentation: Blood and Urine-based Liquid Biopsy Solutions for TMB and MRD in Clinical Trials In this talk, we’ll present the development and clinical applications of blood and urine-based liquid biopsy solutions using cfDNA...
Date: February 13 – 15, 2020 Location: Moscone West Building, San Francisco, CA In collaboration with Mayo Clinic, Lee Moffitt Cancer Center, Monash University, and Kintor Pharmaceuticals, we are proud to announce our 3 abstracts in prostate cancer at the American Society of Clinical Oncology – Genitourinary Cancers Symposium. Stop by our poster presentations or...
Date: January 13 – 16, 2020 Location: Hilton Miami Downtown, Miami, FL In collaboration with Merck KGaA, we are proud to present “Simultaneous multi-parametric profiling of cell-free RNA (cfRNA) and cell-free tumor DNA (ctDNA) in advanced-stage colorectal cancer” at the AACR Special Conference on Advances in Liquid Biopsies, on Tuesday, January 14th at 4:00pm, poster...
Predicine is committed to supporting next-generation scientists in biomedical sciences. Through Predicine Translational Research Award at Harvard Medical School’s New England Science Symposium 2020 (NESS), we encourage students and fellows to innovate and explore careers in STEM. Every year students and fellows from around the U.S. and the world converge at the NESS to share their research...
September 27 – October 1, 2019 Barcelona, Spain Poster presentation: Peripheral cytotoxic T cell correlates with tumor mutational burden and is predictive for progression free survival in advanced breast cancer
August 20 – 22, 2019 Washington DC Details: Exhibition booth # 205 Presentation: Reshaping Oncology Drug Development Landscape with ctDNA + ctRNA Liquid Biopsy Solutions | August 20, 2019
May 31-June 4, 2019 Chicago, IL Details: Exhibition booth #19135 Satellite symposium: New Era of Biomarker-driven Clinical Trials and Regulatory Approvals in US and China |June 1, 2019 Poster Presentations: Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant...
March 31 – April 3, 2019 Atlanta, Georgia Details: Exhibition booth #4322 Satellite symposium: Biomarker-driven Precision Oncology | March 31, 2019 Poster Presentations: Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients https://www.abstractsonline.com/pp8/#!/6812/presentation/4859 Combined immunohistochemistry and NGS-based patient profiling for predicting anti-PD-1/PD-L1 therapy...
October 19-23, 2018 Munich, Germany Poster presentation: Circulating tumor DNA and RNA as an exploratory biomarker to evaluate GT0918 in a phase I/II clinical trial in mCRPC patients https://academic.oup.com/annonc/article/29/suppl_8/mdy269.162/5141769?searchresult=1
